(2)
Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment
Nearly half of people were treated with faricimab every 16 weeks during the first year - the first time this level of durability has been achieved in a phase III study of an injectable eye medicine for neovascular age-related macular degeneration
Faricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways - via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) - that drive a number of retinal conditions
French
Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will take place on 16 March 2021 without the physical presence of shareholders and with only the persons required by the Articles of Incorporation in attendance
During the Annual General Meeting, shareholders rights will be exercised exclusively via the independent proxy, without the physical presence of shareholders
Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not be possible for shareholders to attend the Annual General Meeting in person owing to the ongoing pandemic. Our main concern is to protect our shareholders from any potential health risks that may arise because of the ongoing difficult pandemic situation.
(2)
Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will take place on 16 March 2021 without the physical presence of shareholders and with only the persons required by the Articles of Incorporation in attendance
During the Annual General Meeting, shareholders rights will be exercised exclusively via the independent proxy, without the physical presence of shareholders
Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not be possible for shareholders to attend the Annual General Meeting in person owing to the ongoing pandemic. Our main concern is to protect our shareholders from any potential health risks that may arise because of the ongoing difficult pandemic situation.
New agreement covers 1.25 million additional doses of the antibody cocktail, bringing the total potential US supply to over 1.5 million dosesCasirivimab.
F. Hoffmann-La Roche Ltd: Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
19.2
6.9
18.1
Tecentriq + Avastin (n=133)
24.0
(0.35-0.80)
Median follow-up: 15.6 months.
CR, complete response; DOR, duration of response; HR, hazard ratio; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression free response; PR, partial response; SD, stable disease.
See below for OS data from the primary analysis.
About the IMbrave150 study
IMbrave150 is a global Phase III, multicentre, open-label study of 501 people with unresectable HCC who had not received prior systemic therapy. People were randomised 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously (IV), 1200 mg on day 1 of each 21-day cycle, and Avastin was administered IV, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib wa